Heart-healthy NSAIDs?
This article was originally published in The Tan Sheet
Executive Summary
University of Pennsylvania researchers believe the findings of their new study suggest "the possibility of a new class of nonsteroidal anti-inflammatory drugs (NSAIDs) that steer clear of heart-disease risk and work to reduce it," according to a UPenn release. Deleting the inflammation enzyme microsomal (m)-PGE synthase (PGES)-1 gene in mice predisposed to hardening of the arteries had a "dramatic effect" on the development of atherosclerosis in male and female mice, Miao Wang, PhD, School of Medicine, UPenn, et al., found. Moreover, the deletion of mPGES-1 did not raise blood pressure or predispose the mice to thrombosis like COX-2 inhibition or deletion, the authors report in the Sept. 14 online edition of the Proceedings of the National Academy of Sciences. The PNAS study builds on a study published by the researchers earlier this year in the Journal of Clinical Investigation (1"The Tan Sheet" April 17, 2006, p. 8). The Journal of the American Medical Association released a study this week highlighting the cardiovascular risks associated with taking COX-2s...
You may also be interested in...
COX-2 Heart Risk Mechanism Suggested By Mouse Study Results
Researchers may have identified the mechanism by which COX-2 inhibitors contribute to the risk of cardiovascular events, a study published in the April Journal of Clinical Investigation finds
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.